{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2023:BVFLGAODE2YAS2JUOMUURAXYUR","short_pith_number":"pith:BVFLGAOD","canonical_record":{"source":{"id":"2304.03476","kind":"arxiv","version":2},"metadata":{"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2023-04-07T04:48:33Z","cross_cats_sorted":[],"title_canon_sha256":"da4a35e1d381f60c76a092805418c2b04a3a20699476421e23fb3d4a3a8c0589","abstract_canon_sha256":"b600cbdd0298e3a2ec628c5602f237ecbc04ec1795727d1dce7c51e49c63ec61"},"schema_version":"1.0"},"canonical_sha256":"0d4ab301c326b009693473294882f8a468727570623ec9f0a77ed04d9073d8a6","source":{"kind":"arxiv","id":"2304.03476","version":2},"source_aliases":[{"alias_kind":"arxiv","alias_value":"2304.03476","created_at":"2026-07-05T07:28:44Z"},{"alias_kind":"arxiv_version","alias_value":"2304.03476v2","created_at":"2026-07-05T07:28:44Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2304.03476","created_at":"2026-07-05T07:28:44Z"},{"alias_kind":"pith_short_12","alias_value":"BVFLGAODE2YA","created_at":"2026-07-05T07:28:44Z"},{"alias_kind":"pith_short_16","alias_value":"BVFLGAODE2YAS2JU","created_at":"2026-07-05T07:28:44Z"},{"alias_kind":"pith_short_8","alias_value":"BVFLGAOD","created_at":"2026-07-05T07:28:44Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2023:BVFLGAODE2YAS2JUOMUURAXYUR","target":"record","payload":{"canonical_record":{"source":{"id":"2304.03476","kind":"arxiv","version":2},"metadata":{"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2023-04-07T04:48:33Z","cross_cats_sorted":[],"title_canon_sha256":"da4a35e1d381f60c76a092805418c2b04a3a20699476421e23fb3d4a3a8c0589","abstract_canon_sha256":"b600cbdd0298e3a2ec628c5602f237ecbc04ec1795727d1dce7c51e49c63ec61"},"schema_version":"1.0"},"canonical_sha256":"0d4ab301c326b009693473294882f8a468727570623ec9f0a77ed04d9073d8a6","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-07-05T07:28:44.049118Z","signature_b64":"T6knU3FgSlmwFU7Z0W0vTBBurOQK110l0hlGoG2FPIwCl7IFQV5UeqVwPcX/+yLTDGELYiQYDDO7lFB/+R4nDA==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"0d4ab301c326b009693473294882f8a468727570623ec9f0a77ed04d9073d8a6","last_reissued_at":"2026-07-05T07:28:44.048654Z","signature_status":"signed_v1","first_computed_at":"2026-07-05T07:28:44.048654Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"2304.03476","source_version":2,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-07-05T07:28:44Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"OGKNOlBUay0fcxoRi3W2mxFA+dTNCjsoudk7JRD62bHjHiQ/QbJl5op1VtPLownshx2LJTEggJgA7Dk9ORZHBw==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-08-17T12:49:09.918169Z"},"content_sha256":"92d87c600415f00fcd22b8b254b27906496f8670c8ca3e0fcf9c8a0f455475e3","schema_version":"1.0","event_id":"sha256:92d87c600415f00fcd22b8b254b27906496f8670c8ca3e0fcf9c8a0f455475e3"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2023:BVFLGAODE2YAS2JUOMUURAXYUR","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"Generalizing the intention-to-treat effect of an active control against placebo from historical placebo-controlled trials to an active-controlled trial: A case study of the efficacy of daily oral TDF/FTC in the HPTN 084 study","license":"http://creativecommons.org/licenses/by/4.0/","headline":"","cross_cats":[],"primary_cat":"stat.ME","authors_text":"Bo Zhang, Fei Gao, Oliver Dukes, Qijia He, Sinead Delany-Moretlwe","submitted_at":"2023-04-07T04:48:33Z","abstract_excerpt":"In many clinical settings, an active-controlled trial design (e.g., a non-inferiority or superiority design) is often used to compare an experimental medicine to an active control (e.g., an FDA-approved, standard therapy). One prominent example is a recent phase 3 efficacy trial, HIV Prevention Trials Network Study 084 (HPTN 084), comparing long-acting cabotegravir, a new HIV pre-exposure prophylaxis (PrEP) agent, to the FDA-approved daily oral tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) in a population of heterosexual women in 7 African countries. One key complication of interp"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2304.03476","kind":"arxiv","version":2},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"integrity":{"clean":true,"summary":{"advisory":0,"critical":0,"by_detector":{},"informational":0},"endpoint":"/pith/2304.03476/integrity.json","findings":[],"available":true,"detectors_run":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938"},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-07-05T07:28:44Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"FRF5QmDaHM4viWbq3ECCxt4wduww0FKMN95rW99QD+vnF+yYmgU9W19O0mACsRi2Jyu1ydiEWLKxptwvEoa3Ag==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-08-17T12:49:09.918665Z"},"content_sha256":"01c1d1883a7a9f43e06a5eea19d716f0277c2b861ef7956dd2f306bdeca831d3","schema_version":"1.0","event_id":"sha256:01c1d1883a7a9f43e06a5eea19d716f0277c2b861ef7956dd2f306bdeca831d3"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/BVFLGAODE2YAS2JUOMUURAXYUR/bundle.json","state_url":"https://pith.science/pith/BVFLGAODE2YAS2JUOMUURAXYUR/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/BVFLGAODE2YAS2JUOMUURAXYUR/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-08-17T12:49:09Z","links":{"resolver":"https://pith.science/pith/BVFLGAODE2YAS2JUOMUURAXYUR","bundle":"https://pith.science/pith/BVFLGAODE2YAS2JUOMUURAXYUR/bundle.json","state":"https://pith.science/pith/BVFLGAODE2YAS2JUOMUURAXYUR/state.json","well_known_bundle":"https://pith.science/.well-known/pith/BVFLGAODE2YAS2JUOMUURAXYUR/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2023:BVFLGAODE2YAS2JUOMUURAXYUR","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"b600cbdd0298e3a2ec628c5602f237ecbc04ec1795727d1dce7c51e49c63ec61","cross_cats_sorted":[],"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2023-04-07T04:48:33Z","title_canon_sha256":"da4a35e1d381f60c76a092805418c2b04a3a20699476421e23fb3d4a3a8c0589"},"schema_version":"1.0","source":{"id":"2304.03476","kind":"arxiv","version":2}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"2304.03476","created_at":"2026-07-05T07:28:44Z"},{"alias_kind":"arxiv_version","alias_value":"2304.03476v2","created_at":"2026-07-05T07:28:44Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2304.03476","created_at":"2026-07-05T07:28:44Z"},{"alias_kind":"pith_short_12","alias_value":"BVFLGAODE2YA","created_at":"2026-07-05T07:28:44Z"},{"alias_kind":"pith_short_16","alias_value":"BVFLGAODE2YAS2JU","created_at":"2026-07-05T07:28:44Z"},{"alias_kind":"pith_short_8","alias_value":"BVFLGAOD","created_at":"2026-07-05T07:28:44Z"}],"graph_snapshots":[{"event_id":"sha256:01c1d1883a7a9f43e06a5eea19d716f0277c2b861ef7956dd2f306bdeca831d3","target":"graph","created_at":"2026-07-05T07:28:44Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"integrity":{"available":true,"clean":true,"detectors_run":[],"endpoint":"/pith/2304.03476/integrity.json","findings":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938","summary":{"advisory":0,"by_detector":{},"critical":0,"informational":0}},"paper":{"abstract_excerpt":"In many clinical settings, an active-controlled trial design (e.g., a non-inferiority or superiority design) is often used to compare an experimental medicine to an active control (e.g., an FDA-approved, standard therapy). One prominent example is a recent phase 3 efficacy trial, HIV Prevention Trials Network Study 084 (HPTN 084), comparing long-acting cabotegravir, a new HIV pre-exposure prophylaxis (PrEP) agent, to the FDA-approved daily oral tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) in a population of heterosexual women in 7 African countries. One key complication of interp","authors_text":"Bo Zhang, Fei Gao, Oliver Dukes, Qijia He, Sinead Delany-Moretlwe","cross_cats":[],"headline":"","license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2023-04-07T04:48:33Z","title":"Generalizing the intention-to-treat effect of an active control against placebo from historical placebo-controlled trials to an active-controlled trial: A case study of the efficacy of daily oral TDF/FTC in the HPTN 084 study"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2304.03476","kind":"arxiv","version":2},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:92d87c600415f00fcd22b8b254b27906496f8670c8ca3e0fcf9c8a0f455475e3","target":"record","created_at":"2026-07-05T07:28:44Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"b600cbdd0298e3a2ec628c5602f237ecbc04ec1795727d1dce7c51e49c63ec61","cross_cats_sorted":[],"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2023-04-07T04:48:33Z","title_canon_sha256":"da4a35e1d381f60c76a092805418c2b04a3a20699476421e23fb3d4a3a8c0589"},"schema_version":"1.0","source":{"id":"2304.03476","kind":"arxiv","version":2}},"canonical_sha256":"0d4ab301c326b009693473294882f8a468727570623ec9f0a77ed04d9073d8a6","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"0d4ab301c326b009693473294882f8a468727570623ec9f0a77ed04d9073d8a6","first_computed_at":"2026-07-05T07:28:44.048654Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-07-05T07:28:44.048654Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"T6knU3FgSlmwFU7Z0W0vTBBurOQK110l0hlGoG2FPIwCl7IFQV5UeqVwPcX/+yLTDGELYiQYDDO7lFB/+R4nDA==","signature_status":"signed_v1","signed_at":"2026-07-05T07:28:44.049118Z","signed_message":"canonical_sha256_bytes"},"source_id":"2304.03476","source_kind":"arxiv","source_version":2}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:92d87c600415f00fcd22b8b254b27906496f8670c8ca3e0fcf9c8a0f455475e3","sha256:01c1d1883a7a9f43e06a5eea19d716f0277c2b861ef7956dd2f306bdeca831d3"],"state_sha256":"7162bdc157c0a1c77de2a4c8cdff7ae24cb6e8f635e6cdf89baa247795b52dbe"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"OXezCZz3e/S86VlyMs00brPMtZQ+bpqziAXkvPmSyZkN0lGM89hAX02tDWhP5eXoEeX6ACZIpkbBtQnJvWd/Cg==","signed_message":"bundle_sha256_bytes","signed_at":"2026-08-17T12:49:09.926805Z","bundle_sha256":"07833bdcf336ac1a691989838ae34f0985d3c1473d6a542d5b0fdd274fddfc98"}}